Compounds > sri 62-834
Page last updated: 2024-12-07

sri 62-834

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SRI 62-834: related to ET-18-OCH(3); MLS-266-337 is (R(+))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130724
CHEMBL ID155690
MeSH IDM0156147

Synonyms (18)

Synonym
nsc-614383
nsc614383
sdz 266336 (s isomer)
CHEMBL155690
[2-(octadecoxymethyl)oxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate
crc 86-05
nsc 614383
sdz 266337 (r isomer)
ethanaminium, 2-((hydroxy((tetrahydro-2-((octadecyloxy)methyl)-2-furanyl)methoxy)phosphinyl)oxy)-n,n,n-trimethyl-, hydroxide, inner salt, (+-)-
mls 266-337
sri 62-834
sri 62834
2-((hydroxy-((2-((octadecyloxy)methyl)tetrahydrofuran-2-yl)methoxy)phosphinyl)oxy)-n,n,n-trimethylethylaminium hydroxide inner salt
113201-37-9
(tetrahydro-2-(octadecycloxy)methylfuran-2-yl)methoxyphosphocholine
sri-62-834
{2-[(octadecyloxy)methyl]oxolan-2-yl}methyl 2-(trimethylazaniumyl)ethyl phosphate
DTXSID90921013
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID220065Antitumor activity against YAC-1 tumor cells at concentration 5 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID220066Antitumor activity against YAC-1 tumor cells at concentration 5 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98629Antitumor activity against L1210 cells at concentration 3 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID220061Antitumor activity against YAC-1 tumor cells at concentration 1 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID32552Antitumor activity against Abelson-8.1 cells at concentration 1 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98631Antitumor activity against L1210 cells at concentration 5 ug/mL and at 72 hr and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID32554Antitumor activity against Abelson-8.1 cells at concentration 3 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID32551Antitumor activity against Abelson-8.1 cells at concentration 1 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109845Antitumor activity against mouse macrophages after day 21 at dose 0.25 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98633Antitumor activity against L1210 cells at concentration 5 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109843Antitumor activity against mouse macrophages after day 14 at dose 0.25 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109850Antitumor activity against mouse macrophages after day 7 at dose 0.25 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID154299Antitumor activity against P815 cells at concentration 3 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID154300Antitumor activity against P815 cells at concentration 5 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID120307Mouse survived after 28 days at 0.25 mg/kg; 2/101996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98630Antitumor activity against L1210 cells at concentration 3 ug/mL using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID220064Antitumor activity against YAC-1 tumor cells at concentration 3 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID32553Antitumor activity against Abelson-8.1 cells at concentration 3 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98627Antitumor activity against L1210 cells at concentration 1 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109847Antitumor activity against mouse macrophages after day 28 at dose 0.25 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109851Antitumor activity against mouse macrophages after day 7 at dose 2.50 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109844Antitumor activity against mouse macrophages after day 14 at dose 2.50 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID32555Antitumor activity against Abelson-8.1 cells at concentration 5 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID154301Antitumor activity against P815 cells at concentration 1 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID120308Mouse survived after 28 days at 0.25 mg/kg; 3/101996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98626Antitumor activity against L1210 cells at concentration 1 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID220062Antitumor activity against YAC-1 tumor cells at concentration 1 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98632Antitumor activity against L1210 cells at concentration 5 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID32556Antitumor activity against Abelson-8.1 cells at concentration 5 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID120312Mouse survived after 28 days at 2.5 mg/kg; 6/101996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID154303Antitumor activity against P815 cells at concentration 5 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID154302Antitumor activity against P815 cells at concentration 3 ug/mL and at 72 hr using direct cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID154298Antitumor activity against P815 cells at concentration 1 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID220063Antitumor activity against YAC-1 tumor cells at concentration 3 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109848Antitumor activity against mouse macrophages after day 28 at dose 2.50 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID120309Mouse survived after 28 days at 0.25 mg/kg; 8/101996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID109846Antitumor activity against mouse macrophages after day 21 at dose 2.50 mg/kg by peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
AID98628Antitumor activity against L1210 cells at concentration 3 ug/mL and at 72 hr using Activated Macrophage Cytotoxicity assay.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (12.50)18.7374
1990's14 (87.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		4.9240phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
edelfosine
edelfosine: RN given refers to parent cpd. edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.. 1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.		5.690glycerophosphocholine
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine: reported to have same biological activity as natural PAF-acether; RN given refers to parent cpd without isomeric designation		1.9710
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		4.9240phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
corticosterone
[no description available]		1.981011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
thiazoles
[no description available]		2.38201,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		1.9910acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
ilmofosine
ilmofosine: used in treatment of colonic adenocarcinoma in rats; structure given in first source; RN given refers to hydroxide inner salt		4.730
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.3820organic bromide saltcolorimetric reagent;
dye
web 2086
WEB 2086: structure given in first source; PAF antagonist		7.6730organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.67301,2,3-triazole
quin2-acetoxymethyl ester
Quin2-acetoxymethyl ester: structure given in first source		1.9710
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.		2.67302-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran
2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran: orally active & competitive receptor antagonist of platelet activating factor; structure given in first source		1.9710
ethylene-2,2'-bis(dithio)bis(ethanol)
[no description available]		3.110
dihydrocyclosporin d
dihydrocyclosporin D: RN given refers to (3R,4R)-isomer		1.9810
myelin basic protein
Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.		1.9810
lysophosphatidylcholines
lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.		1.98101-O-acyl-sn-glycero-3-phosphocholine
phosphorus
Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.		1.9810monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		3.7830
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		01.9910
Autoimmune Disease
[description not available]		01.9810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.3920
Allergic Encephalomyelitis
[description not available]		07.3920
MS (Multiple Sclerosis)
[description not available]		02.3920
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		01.9810
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		02.3920
Black Fever
[description not available]		02.910
African Sleeping Sickness
[description not available]		02.910
American Trypanosomiasis
[description not available]		02.910
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.910
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		02.910
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.910
Adenocarcinoma, Basal Cell
[description not available]		01.9810
Experimental Hepatoma
[description not available]		01.9810
Cancer of Lung
[description not available]		01.9810
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9810
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9810
Chronic Illness
[description not available]		01.9810
Recrudescence
[description not available]		01.9810
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		01.9810
Acute Promyelocytic Leukemia
[description not available]		02.3820
Animal Mammary Carcinoma
[description not available]		01.9710
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		02.3820
Di Guglielmo Disease
[description not available]		01.9710
Leukemia, Myeloid, Acute, M4
[description not available]		01.9710
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.		01.9710
Leukemia, Myelomonocytic, Acute
A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.		01.9710
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		01.9710